Gustavo Verdier, BSc, BPharm, MBA

ViiV Healthcare, Montréal, QC, Canada, Canada

Disclosure(s): ViiV Healthcare: Employee

Poster(s):

• (P-537) PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a diverse sample of people with HIV-1 reporting high treatment satisfaction, good adherence, and high quality of life
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-574) Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living with HIV-1 from Pregnancy Data with Combination DTG and/or 3TC Antiretroviral Therapies
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT